Concepedia

A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology · 2009 · 193 citations · 0 references

Concepts

MedicineOncologyPharmacotherapyChemotherapyOncology PharmacotherapyThoracic OncologyCombination ChemotherapyLung Cancer PharmacotherapyErlotinib TherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer Treatment

Abstract

LBA8002 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]